Natus Medical Incorporated (NASDAQ:BABY) reported Q2 2017 earnings this Morning, coming in at $0.34 per share, beating Wall Street’s estimates of $0.33 per Share. Revenue for the quarter came in at $122.20 million beating analyst estimates of $121.99 million
Analyst Coverage For Natus Medical Incorporated (NASDAQ:BABY)
These are 1 Sell Rating, 1 Hold Rating, 1 Buy Rating .
The current consensus rating for Natus Medical Incorporated (NASDAQ:BABY) is Hold (Score: 2.00) with a consensus target price of $47.00 , a potential (22.24% upside)Recent Insider Trading for Natus Medical Incorporated (NASDAQ:BABY)
- On 6/15/2017 James B Hawkins, Insider, bought 4,000 with an average share price of $33.98 per share and the total transaction amounting to $135,920.00.
- On 5/31/2017 James B. Hawkins, Insider, bought 6,000 with an average share price of $33.81 per share and the total transaction amounting to $202,860.00.
- On 5/25/2017 Doris Engibous, Director, sold 5,000 with an average share price of $32.68 per share and the total transaction amounting to $163,400.00.
- On 2/9/2017 Robert A Gunst, Director, sold 5,000 with an average share price of $36.00 per share and the total transaction amounting to $180,000.00.
- On 12/16/2016 James B Hawkins, Insider, bought 10,000 with an average share price of $35.20 per share and the total transaction amounting to $352,000.00.
- On 10/27/2016 James B Hawkins, Insider, bought 10,000 with an average share price of $38.30 per share and the total transaction amounting to $383,000.00.
Recent Trading for Natus Medical Incorporated (NASDAQ:BABY) Shares of Natus Medical Incorporated closed the previous trading session at 37.50 down -0.95 -2.47% with 733,088 shares trading hands.